Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 11/20 | 0.78 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.62 |
| ▸ | MALT1 | Q9UDY8 | 7/20 | 0.55 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.53 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9941441 | 0.88 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL15460590 | 0.82 | EPHX2 (0.89) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL15460594 | 0.81 | EPHX2 (0.86) | EPHX2PTGS2 | |
| SCHEMBL15460592 | 0.80 | EPHX2 (0.77) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL9941597 | 0.80 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL9938827 | 0.78 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL9939025 | 0.78 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL31738522 | 0.78 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL15463053 | 0.78 | PTGS2 (0.80) | EPHX2PTGS2AKR1C3 | |
| SCHEMBL9939539 | 0.78 | EPHX2 (1.00) | EPHX2PTGS2AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2024-01-25 | — | — | US | disclosed |
| US-9096532-B2 | Pyrazole inhibitors of COX-2 and sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-06 | — | — | US | disclosed |
| WO-2012082647-A2 | PYRAZOLE INHIBITORS OF COX-2 AND sEH | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024302-A1 | SOLUBLE EPOXIDE HYDROLASE (sEH) INHIBITORS AND DUAL COX/sEH INHIBITORS FOR THE TREATMENT OF ARRHYTHMOGENIC CARDIOMYOPATHY | EPHX1, EPHX2, PTGER1 | EPHX2 2/4885PTGS2 8/4885MALT1 2094/4885 |
| US-20140038923-A1 | PYRAZOLE INHIBITORS OF COX-2 AND SEH | PTGES2, PTGS2, PTGES3 | EPHX2 5/4885PTGS2 2/4885MALT1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.